Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipatasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 known ✓ | Q9Y243 | 20/20 | 0.98 |
| ▸ | AKT1 known ✓ | P31749 | 19/20 | 0.98 |
| ▸ | AKT2 known ✓ | P31751 | 19/20 | 0.98 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.98 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipatasertib SCHEMBL21900357 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL29393010 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL192342 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL29409453 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191805 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL15390761 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL1740213 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL21900358 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL19867534 | 0.99 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191492 | 0.99 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858989-B9 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH INC (US) | 2021-04-14 | — | — | EP | claimed |
| EP-3719014-A1 | SOLID FORMS OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | Genentech, Inc. (US) | 2020-10-07 | — | — | EP | claimed |
| EP-2858989-B1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH INC (US) | 2020-05-06 | — | — | EP | claimed |
| US-9505725-B2 | Crystalline and mesomorphous forms of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | claimed |
| US-20160152575-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH, INC. (US) | 2016-06-02 | — | — | US | claimed |
| US-9290458-B2 | Amorphous form of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof | GENENTECH, INC. (US) | 2016-03-22 | — | — | US | claimed |
| US-20150274677-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH, INC. | 2015-10-01 | — | — | US | claimed |
| EP-2858989-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL - CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | Genentech, Inc. (US) | 2015-04-15 | — | — | EP | claimed |
| WO-2013173811-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL - CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH, INC. (US) | 2013-11-21 | — | — | WO | claimed |
| CN-112898210-B | Process for preparing pyrimidinylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2025-02-21 | — | — | CN | disclosed |
| EP-4282973-A2 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3656764-B1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-05 | — | — | EP | disclosed |
| CN-110590606-B | Process for preparing pyrimidylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-105899492-B | Process for preparing pyrimidylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2021-08-24 | — | — | CN | disclosed |
| EP-2858989-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL - CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | Genentech, Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2858989-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL - CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | Genentech, Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| CN-104470912-A | Amorphous form of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof | GENENTECH INC | 2015-03-25 | — | — | CN | disclosed |
| WO-2013173811-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL - CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| WO-2013173811-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL - CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274677-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | PIK3CA, PIK3CD, AKT1S1 | AKT3 7/4885AKT1 5/4885AKT2 4/4885 |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | PIK3CA, PIK3CD, PIK3CG | AKT3 20/4885AKT1 10/4885AKT2 6/4885 |
| US-20160152575-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | PIK3CA, PIK3CD, AKT1S1 | AKT3 7/4885AKT1 5/4885AKT2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.